.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Accenture
Julphar
Farmers Insurance
Dow
Cipla
McKesson
Colorcon
US Department of Justice
Harvard Business School
Daiichi Sankyo

Generated: December 14, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title: Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
Abstract:The subject invention provides R(+)-N-propargyl-1-aminoindan and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions containing same. The subject invention also provides methods of treating a subject afflicted with Parkinson's disease, a memory disorder, dementia, depression, hyperactive syndrome, an effective illness, a neurodegenerative disease, a neurotoxic injury, stroke, brain ischemia, a head trauma injury, a spinal trauma injury, neurotrauma, schizophrenia, an attention deficit disorder, multiple sclerosis, or withdrawal symptoms, using R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt of the subject invention. The subject invention further provides a method of preventing nerve damage in a subject. Finally, the subject invention provides methods of preparing R(+)-N-propargyl-1-aminoindan, a salt thereof, and racemic N-propargyl-1-aminoindan.
Inventor(s): Youdim; Moussa B. H. (Tivon, IL), Finberg; John P. M. (Tivon, IL), Levy; Ruth (Tel-Aviv, IL), Sterling; Jeffrey (Jerusalem, IL), Lerner; David (Jerusalem, IL), Yellin; Haim (Ramat-Gan, IL), Veinberg; Alex (Rehovot, IL)
Assignee: Teva Pharmaceutical Industries, Ltd. (Petach-Tikva, IL) Technion Research and Development Foundation Ltd. (Haifa, IL)
Filing Date:Nov 27, 2002
Application Number:10/305,478
Claims:1. A pharmaceutically acceptable salt of R(+)-N-propargyl-1-aminoindan, wherein the salt is the tartrate salt.

2. A pharmaceutical composition consisting essentially of the pharmaceutically acceptable salt of claim 1 and a pharmaceutically acceptable carrier.

3. A pharmaceutical composition comprising the pharmaceutically acceptable salt of claim 1 and a pharmaceutically acceptable carrier.

4. A pharmaceutical composition consisting of the pharmaceutically acceptable salt of claim 1 and a pharmaceutically acceptable carrier.

5. A pharmaceutical composition consisting of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt and a carrier.
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
US Department of Justice
Teva
Healthtrust
Mallinckrodt
Farmers Insurance
US Army
Queensland Health
Fish and Richardson
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot